ImpediMed (IPD) investor relations material

Leadership transition and board remarks

• New CEO Erik Anderson begins, succeeding Parmjot Bains, who will remain as advisor until June 2026.

• Board highlights significant operational and commercial progress under outgoing leadership.

• Erik Anderson brings deep U.S. medtech experience, notably from Hologic, and is tasked with accelerating U.S. commercial execution.

• Board expresses confidence in Erik’s ability to drive the next phase of growth.

• Parmjot Bains is recognized for transforming the business and establishing strong foundations.

Strategic and commercial progress

• SOZO platform’s addressable market expanded with new clinical indications in body composition and heart health.

• U.S. reimbursement coverage for BCRL now reaches 93% of covered lives, a major commercial milestone.

• Annual recurring revenue and installed base have grown, with a strong pipeline for the second half of the financial year.

• Clear strategy and robust foundations set the stage for scaled execution.

Incoming CEO’s vision and priorities

• Erik Anderson aims to accelerate revenue growth by leveraging broad reimbursement and deepening U.S. health system engagement.

• Focus areas include expanding into new hospital networks, supporting clinician adoption, and maintaining financial discipline.

• Plans to build on existing strategy, emphasizing acceleration rather than change.

• Intends to use experience in market access and distribution to drive enterprise-wide adoption.